Growth factor-triggered de-sialylation controls glycolipid-lectin-driven endocytosis.
Title | Growth factor-triggered de-sialylation controls glycolipid-lectin-driven endocytosis. |
Publication Type | Journal Article |
Year of Publication | 2025 |
Authors | MacDonald E, Forrester A, Valades-Cruz CA, Madsen TD, Hetmanski JHR, Dransart E, Ng Y, Godbole R, Shp AAkhil, Leconte L, Chambon V, Ghosh D, Pinet A, Bhatia D, Lombard B, Loew D, Larsen MR, Leffler H, Lefeber DJ, Clausen H, Blangy A, Caswell P, Shafaq-Zadah M, Mayor S, Weigert R, Wunder C, Johannes L |
Journal | Nat Cell Biol |
Date Published | 2025 Feb 21 |
ISSN | 1476-4679 |
Abstract | Glycolipid-lectin-driven endocytosis controls the formation of clathrin-independent carriers and the internalization of various cargos such as β1 integrin. Whether this process is regulated in a dynamic manner remained unexplored. Here we demonstrate that, within minutes, the epidermal growth factor triggers the galectin-driven endocytosis of cell-surface glycoproteins, such as integrins, that are key regulators of cell adhesion and migration. The onset of this process-mediated by the Na/H antiporter NHE1 as well as the neuraminidases Neu1 and Neu3-requires the pH-triggered enzymatic removal of sialic acids whose presence otherwise prevents galectin binding. De-sialylated glycoproteins are then retrogradely transported to the Golgi apparatus where their glycan make-up is reset to regulate EGF-dependent invasive-cell migration. Further evidence is provided for a role of neuraminidases and galectin-3 in acidification-dependent bone resorption. Glycosylation at the cell surface thereby emerges as a dynamic and reversible regulatory post-translational modification that controls a highly adaptable trafficking pathway. |
URL | https://pubmed.ncbi.nlm.nih.gov/39984654/ |
DOI | 10.1038/s41556-025-01616-x |
Alternate Journal | Nat Cell Biol |
PubMed ID | 39984654 |
PubMed Central ID | 2914105 |
Grant List | ANR-10-IDEX-0001-02 PSL / / Agence Nationale de la Recherche (French National Research Agency) / ANR-17-CONV-0005 / / Agence Nationale de la Recherche (French National Research Agency) / ANR-19-CE13-0001-01 / / Agence Nationale de la Recherche (French National Research Agency) / ANR-20-CE15-0009-01 / / Agence Nationale de la Recherche (French National Research Agency) / ANR-22-CE11-0030-03 / / Agence Nationale de la Recherche (French National Research Agency) / ANR-11-LABX-0043 / / Agence Nationale de la Recherche (French National Research Agency) / ANR11-LABX-0038 / / Agence Nationale de la Recherche (French National Research Agency) / ANR10-INBS-01 / / Agence Nationale de la Recherche (French National Research Agency) / ANR-10-INBS-04-07 / / Agence Nationale de la Recherche (French National Research Agency) / n°200014 / / Mizutani Foundation for Glycoscience (Mizutani Foundation) / NNF0067602 / / Novo Nordisk Fonden (Novo Nordisk Foundation) / DNRF107 / / Novo Nordisk Fonden (Novo Nordisk Foundation) / DCRPGF\100002go / / Cancer Research UK (CRUK) / 203128/A/16/Z / / Wellcome Trust (Wellcome) / 226804/Z/22/Z / / Wellcome Trust (Wellcome) / LIP-2021-017 / / Leverhulme Trust / |